In vitro Generation and in vivo Effects of Adherent Lymphokine-Activated Killer Cells and IL2 in Patients with Solid Tumors1

2015 ◽  
pp. 293-302 ◽  
Author(s):  
Theresa L. Whiteside ◽  
Marc S. Ernstoff ◽  
Suresh Nair ◽  
John M. Kirkwood ◽  
Ronald B. Herberman
Keyword(s):  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
In Vivo Effects

In Vitro and In Vivo Effects of Cisplatin on the Generation of Lymphokine-Activated Killer Cells

1990 ◽  
Vol 82 (2) ◽  
pp. 139-142 ◽  
Author(s):  
P. Allavena ◽  
P. Pirovano ◽  
C. Bonazzi ◽  
N. Colombo ◽  
A. Mantovani ◽  
...  
Keyword(s):  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
In Vivo Effects

In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation

Transfusion ◽  
1992 ◽  
Vol 32 (1) ◽  
pp. 42-45 ◽  
Author(s):  
IG Schmidt-Wolf ◽  
M Aihara ◽  
RS Negrin ◽  
KG Blume ◽  
NJ Chao
Keyword(s):  
Lymphokine Activated Killer Cells ◽  
Killer Cells

Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells

1992 ◽  
Vol 77 (5) ◽  
pp. 757-762 ◽  
Author(s):  
Frank P. Holladay ◽  
Teresa Heitz ◽  
Gary W. Wood
Keyword(s):  
Brain Tumor ◽  
T Lymphocytes ◽  
Tumor Cells ◽  
Cytotoxic T Lymphocytes ◽  
Lak Cells ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Brain Tumor Cells

✓ Specific immune responses against malignant brain tumors have been difficult to demonstrate. Moreover, immunotherapy has met with little success, despite using lymphocytes with high levels of cytotoxicity against brain tumor cells. Lymphokine-activated killer (LAK) cells that nonspecifically kill brain tumor cells are produced by stimulating resting precursors with high concentrations of interleukin-2 (IL-2). Cytotoxic T lymphocytes that specifically kill brain tumor cells are produced by stimulating antigen receptor-positive immune-cell precursors with tumor cells. In an attempt to gain insight into immune cell function against brain tumors, the present study compared the in vitro and in vivo activities of LAK cells and cytotoxic T lymphocytes produced against RT2, a fast-growing rat glioma cell line. Lymphokine-activated killer cells were produced by stimulating normal rat spleen cells with 1000 units of IL-2, and RT2-specifie cytotoxic T lymphocytes were produced by priming them in vivo with RT2 and Corynebacterium parvum and restimulating primed spleen cells with RT2 in vitro. Lymphokine-activated killer cells were highly cytotoxic for a panel of syngeneic and allogeneic brain tumor and non-brain tumor target cells, including RT2, as measured in a 4-hour 51Cr release assay. Cytotoxic T lymphocytes were highly cytotoxic only for syngeneic brain tumor target cells. Lymphokine-activated killer cells and cytotoxic T lymphocytes were tested for in vivo antitumor activity against intracerebral RT2 by intravenous adoptive transfer of activated lymphocytes. Untreated rats died in approximately 2 weeks. Lymphokine-activated killer cells plus IL-2 failed to affect survival when treatment was initiated as early as 1 day following tumor inoculation. Cytotoxic T lymphocytes and IL-2 administered as late as Day 5 rejected progressing intracerebral tumor. Thus, although both cytotoxic T lymphocytes and LAK cells exhibited high levels of in vitro killing of glioma cells, only cytotoxic T lymphocytes rejected progressing intracerebral tumors.

In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro

1991 ◽  
Vol 132 (2) ◽  
pp. 277-284 ◽  
Author(s):  
Gerald E. Hancock ◽  
Anthony Molloy ◽  
A.B. Birhane Kale ◽  
Rolf Kiessling ◽  
Marijke Becx-Bleumink ◽  
...  
Keyword(s):  
Low Dose ◽  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
In Vivo Administration
Sign in / Sign up

Export Citation Format

Share Document